Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Aposense Ltd.
Petah Tikva, HaMerkaz, Israelaposense.com ↗
- Ownership
- Public · APOS
- Employees
- ~50
- Development stage
- Other
01
Overview
Aposense has developed a patented technology to target apoptotic cells in vivo using rationally designed small molecules. Its lead imaging agent ([18F]-ML10) reached Phase II clinical trials for early detection of tumor response to therapy. The company’s therapeutic pipeline includes ATT‑11T, a Topoisomerase I inhibitor conjugate for solid tumors currently at the preclinical stage. The company also collaborates on siRNA brain delivery platforms and has several academic and industry partnerships.[1][2][4][6]
- Therapeutic areas
- OncologyCardiovascular
- Modalities
- Small moleculessiRNA (genetic drugs)Diagnostic radiopharmaceuticals[2][4][6]
- Industry
- Biotech
02
Partnerships
Teva PharmaceuticalsIBA S.A.Sigma-AldrichBioasis Technologies Inc.[1][2]
Beyond the preview
Go deeper on Aposense Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aposense Ltd..